A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Author： Richter Suzanne   Bedard Philippe   Chen Eric   Clarke Blaise   Tran Ben   Hotte Sebastien   Stathis Anastasios   Hirte Hal   Razak Albiruni   Reedijk Michael   Chen Zhuo   Cohen Brenda   Zhang Wen-Jiang   Wang Lisa   Ivy S.   Moore Malcolm   Oza Amit   Siu Lillian   McWhirter Elaine  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.32, Iss.2, 2014-04, pp. : 243-249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study

By Schmid Peter   Schweigert Marcus   Beinert Thomas   Flath Bernd   Sezer Orhan   Possinger Kurt  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 139-146

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

By Deming Dustin   Ninan Jacob   Bailey Howard   Kolesar Jill   Eickhoff Jens   Reid Joel   Ames Matthew   McGovern Renee   Alberti Dona   Marnocha Rebecca   Espinoza-Delgado Igor   Wright John   Wilding George   Schelman William  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 323-329

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

By Samol Jens  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1493-1500

Springer Publishing Company

Access to resources Recommend Favorite

A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance

By Salzberg Marc   Pless Miklos   Rochlitz Christoph   Ambrus Klara   Scigalla Paul   Herrmann Richard  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 299-304

Springer Publishing Company

Access to resources Recommend Favorite